The regulatory sweep found no new anaesthetic drug approval, device recall or safety communication today. The only application to reach the sweep recently was a supplement on a generic buprenorphine and naloxone product — relevant to opioid-dependent patients presenting for surgery, but not a change of practice. On this desk a quiet regulatory column is the normal state: most of what changes anaesthetic practice is published as society guidance, not as a licensing decision.
The substantive guidance is from the European Malignant Hyperthermia Group. Patients with inherited primary disorders of skeletal muscle can present perioperatively with features that mimic a malignant hyperthermia crisis, and referring clinicians have been working from conflicting and out-of-date literature. Following a literature review and a formal consensus process reviewed at annual meetings and workshops, the group has issued guidelines covering general recommendations for any patient with myopathy requiring anaesthesia or procedural sedation, plus disease-specific recommendations and main concerns for congenital, mitochondrial and metabolic myopathies, the muscular dystrophies, the myotonias and the familial periodic paralyses.
The operational value is that it separates the conditions that genuinely require a trigger-free anaesthetic from the much larger group that do not but have been treated as if they did — and names what the real risk is in each. Note what this sweep does not see: CDSCO notifications, national drug alerts and ISA or AAGBI standards published as web pages are outside it. An empty register is not evidence that nothing was published.
- Do not treat every inherited myopathy as malignant hyperthermia susceptible; the guideline separates them.
- Rhabdomyolysis after succinylcholine in an undiagnosed dystrophinopathy is a different event from a malignant hyperthermia crisis — manage it as such.
- Check dantrolene stock and expiry against your theatre case mix, whatever this guideline says about individual conditions.
- Where a specific myopathy is named preoperatively, look up its own recommendation rather than applying a blanket policy.
- No anaesthetic drug or device safety action was issued today.
The statistics, in plain English
A formal consensus guideline reports agreement, not effect sizes, and for rare conditions that is the only evidence there will ever be — no trial will randomise patients with a specific congenital myopathy. That makes the document authoritative and simultaneously not empirical, and the distinction matters when a recommendation conflicts with a case series you remember.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for anaesthesiology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free